Reporting hours: 15,756
Small businesses are not affected.
General description of report: This report is required by law [12 U.S.C. 248(a)(2), 353 et seq., 602 and 625]. Individual respondent data are given confidential treatment [5 U.S.C. 552(b)(8)].

This report provides a breakdown of foreign branch assets and liabilities by category of customer and between dollars and foreign currencies. Data are used for supervisory purposes, in construction of the monetary aggregates, and to monitor U.S. banks' foreign activities. The revisions include minor changes in reporting instructions and in form items.

5. Report title: Quarterly Report of Foreign Branch Assets and Liabilities
Agency form number: FR 2502S
OMB Docket number: 7100–0079
Frequency: Quarterly
Reporters: Foreign branches of U.S. banks and Edge and Agreement corporations
Reporting hours: 7070
Small businesses are not affected.
General description of report: This report is required by law [12 U.S.C. 248(a)(2), 353 et seq., 602 and 625]. Individual respondent data are given confidential treatment [5 U.S.C. 552(b)(8)].

This report provides a geographic breakdown of assets and liabilities of foreign branch offices of U.S. banks. It is used to monitor U.S. banks' claims on and liabilities to individual foreign countries by particular branch offices and to monitor countries' indebtedness to U.S. banks. The revisions include minor changes in instructions and country names on the form.

6. Report title: Community Reinvestment Act Questionnaire
Agency form number: FR 1283
OMB Docket number: 7100–0052
Frequency: On occasion
Reporters: State member banks
Annual reporting hours: 521
Small businesses are affected.
General description of report: This information collection is mandatory [12 U.S.C. 325 and 12 U.S.C. 2901(b) and is given confidential treatment [5 U.S.C. 552(b)(8)].

The Federal Reserve requests a senior bank officer to complete this form, which is called the Community Reinvestment Act Questionnaire. The form provides information needed to make an assessment, as mandated by the Community Reinvestment Act, regarding the bank's effort to serve the credit needs of its local community. The revisions are minor wording changes to clarify the information being requested.

Board of Governors of the Federal Reserve System, October 1, 1987.
William W. Wiles,
Secretary of the Board.
[FR Doc. 87–23158 Filed 10–6–87; 8:45 am]
BILLING CODE 6210–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Service's claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of the Treasury's current value of funds rate or the applicable rate determined from the "Schedule of Certified Interest Rates with Range of Maturities." This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the **Federal Register.**

The Secretary of the Treasury has certified a rate of 14.25% for the quarter ended September 30, 1987. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Date: October 2, 1987.
Dennis J. Fischer,
Deputy Assistant Secretary, Finance.
[FR Doc. 87–23199 Filed 10–6–87; 8:45 am]
BILLING CODE 41506–04–M

Food and Drug Administration

[Docket No. 87F–0300]

Betz Laboratories, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Betz Laboratories, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of hydroquinone as an additive in boilers producing steam that may come in contact with food.

FOR FURTHER INFORMATION CONTACT: Eric Flamm, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–426–5487.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 7A4031) has been filed by Betz Laboratories, Inc., 4636 Somerton Rd., Trevose, PA 19047, proposing that § 173.310 *Boiler water additives* (21 CFR 173.310) be amended to provide for the safe use of hydroquinone as an additive in boilers producing steam that may come in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Reister** in accordance with 21 CFR 25.40(c).

Dated: September 30, 1987.
Richard J. Ronk,
Acting Director, Center for Food Safety and Applied Nutrition.
[FR Doc. 87–23186 Filed 10–6–87; 8:45 am]
BILLING CODE 4160–01–M

[Docket No. 87F–0302]

E.I. du Pont De Nemours & Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that E.I. du Pont de Nemours & Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a polymer manufactured by the condensation of hexamethylenediamine, terephthalic acid, and isophthalic acid for contact with all types of food, except beverages containing more than 8 percent alcohol.

FOR FURTHER INFORMATION CONTACT: Edward J. Machuga, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAB 7B4001) has been filed by E.I. du Pont de Nemours & Co., Wilmington, DE 19898, proposing that § 177.1500 *Nylon resins* (21 CFR 177.1500) be amended to provide for the safe use of a polymer manufactured by the condensation of hexamethylenediamine, terephthalic

acid, and sophthaic acid for contact with all types of food, except beverages containing more than 8 percent alcohol.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: September 30, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87-23187 Filed 10-6-87; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 87F-0309]

Sherex Chemical Co., Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Sherex Chemical Co., Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a mixture of dodecyltin tri(isooctylmercaptoacetate) and di(dodecyl)tin di(isooctylmercaptoacetate) as a thermal stabilizer for polyvinyl chloride and vinyl chloride copolymers intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 5B3873) has been filed by Sherex Chemical Co., Inc., P.O. Box 646, Dublin, OH 43017, proposing that § 178.2650 *Organotin stabilizers in vinyl chloride plastics* (21 CFR 178.2650) be amended to provide for the safe use of a mixture of dodecyltin tri(isooctylmercaptoacetate) and di(dodecyl)tin di(isooctylmercaptoacetate) as a thermal stabilizer for polyvinyl chloride and vinyl chloride copolymers intended for use in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: September 30, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87-23188 Filed 10-6-87; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 87F-0294]

Sumitomo Chemical Co., Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Sumitomo Chemical Co., Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polyvinylcyclohexane as a clarifying agent for polypropylene and olefin copolymers intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 7B4032) has been filed by Sumitomo Chemical Co., Ltd., 7-9 Nihonbashi, 2-Chome, Chuo-ku, Tokyo, Japan, proposing that § 177.1520 *Olefin polymers* (21 CFR 177.1520) be amended to provide for the safe use of polyvinylcyclohexane as a clarifying in polypropylene complying with § 177.1520(c), item 1.1, and olefin copolymers complying with § 177.1520(c), items 3.1 and 3.2, for use in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: September 30, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87-23185 Filed 10-6-87; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 87N-0337]

Drug Export; Carbicarb Injection

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that International Medication Systems, Ltd. (IMS), has filed an application requesting approval for the export of the human drug Carbicarb Injection to Canada and the United Kingdom.

ADDRESS: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Rudolf Apodaca, Center for Drugs and Biologics (HFN-310), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8063.

SUPPLEMENTARY INFORMATION: The Drug Export Amendments Act of 1986 (Pub. L. 99-660) (section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)) provides that FDA may approve applications for the export of drugs that are not currently approved in the United States. The approval process is governed by section 802(b) of the act. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that they agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that International Medication Systems, Ltd. (IMS), 1886 Santa Anita Ave., South El Monte, CA 91733, has filed an application requesting approval for the export of the drug Carbicarb Injection to Canada and the United Kingdom. This drug is indicated for use when correction of the pH is required in conditions of metabolic acidosis such as that related to cardiopulmonary bypass, renal disease, circulation insufficiency due to shock or dehydration, cardiac arrest and primary lactic acidosis. The application was received and filed in the Center for Drugs and Biologics on September 17, 1987, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4.pm., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by October 19, 1987, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802, Pub. L. 99-660 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drugs and Biologics (21 CFR 5.44).

Dated: September 25, 1987.

Daniel L. Michels,

Director, Office of Compliance, Center for Drugs and Biologics.

[FR Doc. 87-23184 Filed 10-6-87; 8:45 am]

BILLING CODE 4160-01-M

Health Care Financing Administration

[BPO-070-GNC]

Medicare Program; Criteria and Standards for Evaluating Intermediary and Carrier Performance During Fiscal Year 1988

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: General notice With comment period.

SUMMARY: This notice describes the criteria and standards to be used for evaluating the performance of fiscal intermediaries and carriers in the administration of the Medicare program for the fiscal year beginning October 1, 1987. The results of these evaluations are considered whenever we enter into, renew, or terminate an intermediary or carrier contract or take other contract actions; assign or reassign providers of services to an intermediary; or designate regional or national intermediaries. In addition, this notice describes the methodology used for identifying contractors for competitive replacement under section 2326 of the Deficit Reduction Act of 1984.

This notice is published in accordance with sections 1816(f) and 1842(b)(2) of the Social Security Act, which requires us to publish for public comment in the **Federal Register**, those criteria and standards against which we evaluate intermediaries and carriers.

DATE: The criteria and standards are effective October 1, 1987. We will consider revising the criteria and standards based on public comments. To assure consideration, comments must be sent to the appropriate address and received by December 7, 1987.

ADDRESSES: Address comments in writing to: Health Care Financing Administration, Department of Health and Human Services, Attention: BPO-070-GNC, P.O. Box 26676, Baltimore, Maryland.

In commenting, please refer to file code BPO-070-GNC.

If you prefer, you may deliver your comments to Room 309-G Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC or to Room 132, East High Rise Building, 6325 Security Boulevard, Baltimore, Maryland.